MRRSE announces addition of new report "Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024" to its database

1. Neurological Disorder Drugs in Europe Market - Increasing
Research and Development Fuels Market Growth
Report Description
Neurological drugs are developed to treat neurological
disorders such as epilepsy, Parkinson’s disease, Alzheimer’s
disease, multiple sclerosis, schizophrenia, traumatic brain

2. injury, spinal cord injury, cerebrovascular diseases, and
others. The growing prevalence of these disorders across the
European region is anticipated to drive the demand for
neurological disorder drugs market in the coming few years.
The research report projects that intensifying concerns about
living an adjusted life have prompted several patients to seek
help. According to the study, the Europe neurological
disorder drugs market was valued is expected to reach a
valuation of US$32.0 bn by the end of 2024 as compared to
US$18.3 bn in 2015. During the forecast years of 2016 and
2024, the overall market is expected to surge at a CAGR of
CAGR of 6.4%.

3. Request a Sample Copy of the Report @
http://www.mrrse.com/sample/2397
Increasing Research and Development Fuels Market Growth
The Europe neurological disorders drugs market will be
fueled by the growing initiatives taken by governments of
several countries to educate the masses and to develop new
drugs. For instance, European Parkinson's Disease Association
in Europe is offering affordable medications to patients,
campaigning to raise awareness, and supporting research and
development activities to drive the overall neurological
disorder drugs market. The market has also seen a steady
emergence of several research and development programs that

4. are focused toward developing effective drugs that come at
affordable prices. The collective rise in the spending of
countries on developing neurological disorder drugs is
expected to improve the market’s revenue in the coming few
years.
Inquiry on this report @ http://www.mrrse.com/enquiry/2397
On the basis of various disorders, the market caters to
disorders such as epilepsy, Parkinson’s disease, Alzheimer’s
disease, multiple sclerosis, cerebrovascular disease and others.
Out of all of these segments, the cerebrovascular disease held
the dominant share in terms of revenue in 2015. The World

5. Health Organization (WHO) states that the cerebrovascular
diseases, which can manifest as a stroke, migraine and
headache is the common cause of worry for several patients.
About 80% of the patients suffering from cerebrovascular
diseases across EU% show these symptoms. Thus, this
segment is expected to exhibit a robust growth rate in the
coming few years.
Germany Stands out as Highest Consumer of Neurological
Disorder Drugs in Europe
In terms of geography, the Europe neurological disorder
drugs market is segmented into Germany, France, Italy,
Spain, U.K., Russia, Netherlands, Switzerland, Poland, and

6. Rest of Europe. The research report states that Germany held
a significant share in the market in 2015, closely followed by
France. The regions will dominate over the forecast period
due to the rising prevalence of neurological disorders and
improving the awareness about the diseases due to support
groups and government initiatives. Furthermore, the rising
pool of geriatrics in Germany will also boost the uptake of
neurological disorders drugs in the coming few years.
Read Complete Report with TOC @
http://www.mrrse.com/europe-neurological-disorder-drugs-
market

7. Presently, Germany, the U.K., France, Switzerland, Italy, and
Spain are the leading countries in Europe in the neurological
disorder drugs market. The study indicates that Switzerland
will offer several growth opportunities to the overall market
as awareness about these life-altering diseases grows.
The leading players operating in the Europe neurological
disorders market are Merck & Co., Boehringer Ingelheim
GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd.,
Teva Pharmaceutical Industries Ltd., Novartis AG, and
GlaxoSmithKline plc. Among these, Merck & Co.,
GlaxoSmithKline plc and Novartis AG. The research report
states that the market is consolidated due to the presence of
several small players in who hold significant share in the

8. market. Most of these companies are focusing on improving
their pipelines and expanding their geographical outreach to
retain their dominance.
About MRRSE
MRRSE stands for Market Research Reports Search Engine,
the largest online catalog of latest market research reports
based on industries, companies, and countries. MRRSE
sources thousands of industry reports, market statistics, and
company profiles from trusted entities and makes them
available at a click. Besides well-known private publishers,
the reports featured on MRRSE typically come from national

9. statistics agencies, investment agencies, leading media houses,
trade unions, governments, and embassies.
Contact US:
Corporate Office
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-730-0559

10. Email: sales@mrrse.com